Arizona State Retirement System Lowers Stock Position in Illumina, Inc. $ILMN

Arizona State Retirement System lessened its holdings in Illumina, Inc. (NASDAQ:ILMN) by 10.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 42,177 shares of the life sciences company’s stock after selling 4,912 shares during the period. Arizona State Retirement System’s holdings in Illumina were worth $5,532,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of ILMN. Capital World Investors lifted its position in shares of Illumina by 20.0% in the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after purchasing an additional 3,331,542 shares during the period. Nordea Investment Management AB lifted its position in shares of Illumina by 2,792.2% in the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock worth $124,145,000 after purchasing an additional 911,843 shares during the period. Massachusetts Financial Services Co. MA purchased a new stake in shares of Illumina in the 4th quarter worth approximately $73,532,000. State Street Corp lifted its position in shares of Illumina by 6.8% in the 3rd quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock worth $569,800,000 after purchasing an additional 382,520 shares during the period. Finally, Duquesne Family Office LLC purchased a new stake in shares of Illumina in the 2nd quarter worth approximately $28,682,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

ILMN has been the subject of several research reports. TD Cowen reaffirmed a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. Guggenheim upped their price target on shares of Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Piper Sandler lowered their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research report on Monday, February 9th. UBS Group reaffirmed a “neutral” rating and issued a $135.00 price target on shares of Illumina in a research report on Friday, February 6th. Finally, Stifel Nicolaus increased their target price on shares of Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Six investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $129.69.

Insider Activity

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the firm’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 2.90% of the company’s stock.

Illumina Stock Performance

NASDAQ:ILMN opened at $127.88 on Monday. Illumina, Inc. has a 52 week low of $73.86 and a 52 week high of $155.53. The firm has a 50 day moving average of $125.10 and a 200 day moving average of $126.02. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $19.43 billion, a price-to-earnings ratio of 23.46, a PEG ratio of 2.45 and a beta of 1.49.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.10 billion. During the same quarter in the prior year, the company posted $0.95 earnings per share. Illumina’s revenue for the quarter was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, sell-side analysts anticipate that Illumina, Inc. will post 5.12 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.